Equities rally as virus surges in U.S.
SummaryMajor U.S. equity indices pushed higher on the week, as positive developments in the hunt for effective COVID-19 treatments and a vaccine improved investor sentiment.
Prior week summary
The major U.S. equity indices pushed higher on the week, notching a second consecutive week of gains, as positive developments in the hunt for both effective COVID-19 treatment options and a viable vaccine improved investor sentiment and outweighed concerns of a renewed surge in virus cases within the U.S. As of Sunday evening, the global infection tally stands just above 13 million cases with nearly 3.5 million confirmed cases originating in the U.S. In recent weeks, some states, particularly in the southern U.S. and California, have seen a renewed surge in virus cases, causing some hotspots to reimpose restrictions on non-essential businesses. On Friday, the U.S. reported over 71,000 new confirmed cases of COVID-19, breaking the previous global record for the largest daily increase in confirmed cases for one country.
Congress is considering another virus relief bill in the coming weeks, aimed at aiding businesses and employees in the hardest-hit industries such as travel and retail companies. Speaking to reporters on Friday, White House Economic Advisor Larry Kudlow, spoke of the desire for a more-targeted bill in this round of stimulus saying, “I think it’s going to be a tighter bill. We can’t keep posting $3, $4 trillion every three months or every two months,” and noted, “The key now is helping folks get back to work. We’ll have some unemployment reforms. We’ll have some re-employment bonuses. We will have some additional economic impact assistance in a targeted way.” Singing a similar tune, Treasury Secretary Steven Mnuchin, said on Thursday that the Trump administration is looking to cap the current unemployment coverage at 100% of pre-virus pay saying, “You can assume it will be no more than 100%, so, yes, we want to incent people to go back to work.” Many market participants were encouraged on Friday by new data released from Gilead Sciences on a study conducted on their antiviral drug, remdesivir. The study reported that remdesivir was associated with a 62% reduction in mortality and 74.4% of patients treated with the drug recovered by day 14 compared to 59.0% of patients who received standard-of-care treatment. Early this morning, Pfizer announced that the experimental vaccine they are developing in conjunction with BioNTech received a “Fast Track” designation by the Food and Drug Administration and expect to manufacture 100 million doses by year-end.
News was light on the economic data front this week. The ISM Non-Manufacturing Index smashed expectations posting a level of 57.1 for June, well above the 45.4 reading in May and the first reading in expansionary territory since March. The increase between May and June marks the biggest month over month increase in the measure since 1997. Many warn that this latest release does not account for the recent surge in virus cases in the U.S., and that may push the index down from its current position in July. Showcasing the deflationary effects of the virus outbreak, the June reading of the Producer Price Index showed prices falling 0.2% compared to a 0.4% increase last month. A host of Federal Reserve officials held speaking engagements throughout the week. Speaking in front of the National Association of Business Economists, San Francisco Federal Reserve President Mary Daly, highlighted the uncertainty around the economic outlook saying, “We don’t know how long it will fully take to put the virus behind us. I am assuming unemployment will level off at someplace we don’t want it to be.”
The look forward
In a busy week for economic data releases, market participants are looking forward to the release of updated figures on the Empire Manufacturing Index, industrial production, retail sales, the Consumer Price Index, and jobless claims, among others.
Market implied policy path (Overnight indexed swap rates)
Chatham Hedging Advisors, LLC (CHA) is a subsidiary of Chatham Financial Corp. and provides hedge advisory, accounting and execution services related to swap transactions in the United States. CHA is registered with the Commodity Futures Trading Commission (CFTC) as a commodity trading advisor and is a member of the National Futures Association (NFA); however, neither the CFTC nor the NFA have passed upon the merits of participating in any advisory services offered by CHA. For further information, please visit chathamfinancial.com/legal-notices.
Transactions in over-the-counter derivatives (or “swaps”) have significant risks, including, but not limited to, substantial risk of loss. You should consult your own business, legal, tax and accounting advisers with respect to proposed swap transaction and you should refrain from entering into any swap transaction unless you have fully understood the terms and risks of the transaction, including the extent of your potential risk of loss. This material has been prepared by a sales or trading employee or agent of Chatham Hedging Advisors and could be deemed a solicitation for entering into a derivatives transaction. This material is not a research report prepared by Chatham Hedging Advisors. If you are not an experienced user of the derivatives markets, capable of making independent trading decisions, then you should not rely solely on this communication in making trading decisions. All rights reserved.20-0225
Our featured insights
Expert conversation with Matt Henry and Jackie Bowie
Matt Henry, Chatham's Managing Partner and CEO, sat down with Jackie Bowie, Managing Partner and Head of Europe. In this interview, Jackie discusses macro and micro economic issues and trends that the U.K. and Europe could be facing going into 2023 and 2024.
Why it’s not too late for interest rate swaps
Bob Newman writes for Bank Director and discusses why community and regional banks should consider using derivatives as a tool to manage interest rate risk.
Banks tightened and the market rallied: what’s going on?
The European Central Bank (ECB), Bank of England (BoE), and U.S. Federal Reserve (Fed) all raised their respective benchmark rates last week. The ECB raised rates by 50 basis points to a key rate of 2.5% on Thursday and signaled another 50-basis-point hike was coming at the next meeting in March....
Big NFP beat sends yields higher
In an eventful week in the financial markets, Treasury yields moved higher, and the major U.S. equity indices ended the week mixed as market participants reacted to a better-than-expected January employment report, solid fourth-quarter earnings releases, and the latest commentary from Fed Chair...
Hikes continue but signs of easing on the horizon?
On 2 February, the European Central Bank (ECB) voted for a further 0.50% interest rate increase in a move widely expected by markets following the hawkish stance of ECB policymakers at the prior meeting. Core inflation remained steady at 5.20%, supporting ECB President Christine Lagarde’s...
A year of Fed interest rate hikes
On Wednesday, February 1, 2023, the Federal Open Market Committee (FOMC) increased interest rates by 25 basis points for a target fed funds range of 450–475. This rate increase marks another decrease in size of these rate hikes, but it shows that the Fed continues applying pressure on inflation....
Back-to-Back Swap Program Benchmark Statistics Report
Our back-to-back swap benchmark report compares customer swap transactions across years, regions, and bank asset size. While your financial institution may not yet be using swaps to win more commercial loan business, you can still find value in reviewing this report.
GDP, PCE take steps in the right direction ahead of Fed meeting, China’s reopening leads to commodities shift
December metrics for GDP and inflation came in at promising levels, keeping market expectations consistent ahead of this week’s FOMC meeting. China’s reopening leads to increased economic activity, including increased demand for metals and oil, while natural gas struggles due to unexpectedly warm...